Hematological Disorders
Sirnaomics doses first patient in anticoagulant treatment trial
US-based biopharmaceutical company Sirnaomics has dosed the first patient in a Phase I clinical trial of STP122G, an RNAi drug…
Pipeline Moves: Hengrui Medicine Phase III breast cancer termination lowers approval prospects
This week on Pipeline Moves, we start by investigating terminations of a Phase III trial in breast cancer, a Phase…
Pipeline Moves: advancement prospects jump for Parkinson’s disease stem cell therapy
This week on Pipeline Moves, we start by looking at completions of Phase II trials in Parkinson’s disease and asthma,…
Imago doses first subject in Phase II myelofibrosis treatment trial
Imago BioSciences has dosed the first subject in the Phase II clinical trial of bomedemstat plus ruxolitinib (Jakafi) in myelofibrosis…
Highlights from the ASH 2022 annual meeting: bispecific antibody updates
At the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on 10–13 December, a lot of the focus…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Roche reports positive data from Phase III PNH therapy trial
Roche has reported positive findings from the Phase III COMMODORE 3 clinical trial, in which its antibody crovalimab achieved disease control in…
Health Canada grants CTA authorisation for QurAlis’ ALS therapy
Health Canada has granted authorisation for the clinical trial application (CTA) of QurAlis for the Phase I ANQUR trial of its therapy,…
TC BioPharm doses first subjects in Phase IIb leukaemia trial
TC Biopharm has dosed the first three subjects in its Phase IIb clinical trial of an allogeneic unmodified cell therapy, OmnImmune, to…
Kyowa Kirin and MEI Pharma report data from Phase II lymphoma trial
Kyowa Kirin and MEI Pharma have reported topline findings from the Phase II MIRAGE clinical trial of zandelisib in indolent…
Pipeline Moves: approval prospects jump for AstraZeneca’s breast cancer drug
This week on Pipeline Moves, we look into the announcements of positive data from two Phase III trials in breast…